Genotypic testing is performed by identifying a pattern of HIV virus mutations obtained from a sample of an individual’s plasma. These specific genetic patterns are associated with resistance to specific antiretrovirals, providing a prediction of susceptibility.
Both tests provide predictions of resistance for all nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs), with additional information about integrase inhibitors provided by GenoSure PRIme.